The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Feher, C
- Munez Rubio, E.
- Merino Amador, P.
- Delgado-Iribarren Garcia-Campero, A.
- Merino, E
- Diaz-Brito, V
- Alvarez, MJ
- Mensa, J
Grupos
Abstract
The objective of this study was to evaluate the efficacy and safety of fidaxomicin in the real-life clinical setting. This was a retrospective cohort of patients with Clostridium difficile infection (CDI) treated with fidaxomicin in 20 Spanish hospitals between July 2013 and July 2014. Clinical cure, 30-day recurrence, 30-day mortality, sustained cure, and factors associated with the failure to achieve sustained cure were analyzed. Of the 72 patients in the cohort 41 (56.9 %) had a fatal underlying disease. There were 44 (61.1 %) recurrent episodes and 26 cases (36.1 %) with a history of multiple recurrences. Most episodes were severe (26, 36 %) or severe-complicated (14, 19.4 %). Clinical cure rate was 90.3 %, recurrence rate was 16.7 % and three patients (4.2 %) died during the follow-up period. Sustained cure was achieved in 52 cases (72.2 %). Adverse events were reported in five cases (6.9 %). Factors associated with the lack of sustained cure were cardiovascular comorbidity (OR 11.4; 95 %CI 1.9-67.8), acute kidney failure (OR 7.4; 95 %CI 1.3-43.1), concomitant systemic antibiotic treatment (OR 6.2; 95 %CI 1.1-36.8), and C-reactive protein value at diagnosis (OR 1.2 for each 1 mg/dl increase; 95 %CI 1.03-1.3). Fidaxomicin is an effective and well tolerable treatment for severe CDI and for cases with elevated recurrence risk.
Datos de la publicación
- ISSN/ISSNe:
- 0934-9723, 1435-4373
- Tipo:
- Article
- Páginas:
- 295-303
- PubMed:
- 27718071
- Factor de Impacto:
- 1,312 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES SPRINGER
Citas Recibidas en Web of Science: 20
Documentos
- No hay documentos
Filiaciones
Keywords
- RISK-FACTORS; CO-MORBIDITY; VANCOMYCIN; PREDICTORS; METAANALYSIS; SUSCEPTIBILITY; MANAGEMENT; VALIDATION; GUIDELINES; DERIVATION
Cita
Feher C,Munez E,Merino P,Delgado A,SALAVERT M,Merino E,MASEDA E,Diaz V,Alvarez MJ,Mensa J. The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort. Eur. J. Clin. Microbiol. Infect. Dis. 2017. 36. (2):p. 295-303. IF:2,537. (2).
Portal de investigación